Stryker Corporation $SYK Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Stryker Corporation (NYSE:SYK) by 27.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,075,336 shares of the medical technology company’s stock after acquiring an additional 444,611 shares during the period. Janus Henderson Group PLC’s holdings in Stryker were worth $729,417,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. VanderPol Investments L.L.C. grew its holdings in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after acquiring an additional 28 shares in the last quarter. KCM Investment Advisors LLC grew its holdings in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares in the last quarter. Rossby Financial LCC grew its holdings in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares in the last quarter. Stonebridge Capital Advisors LLC grew its holdings in Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after acquiring an additional 29 shares in the last quarter. Finally, Tcfg Wealth Management LLC grew its holdings in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SYK has been the subject of several recent analyst reports. William Blair reissued an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Needham & Company LLC reduced their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Company reduced their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Trading Down 3.0%

Shares of NYSE:SYK opened at $301.24 on Thursday. The company has a market cap of $115.48 billion, a PE ratio of 34.87, a P/E/G ratio of 1.99 and a beta of 0.78. The company’s 50-day moving average price is $314.89 and its 200 day moving average price is $342.38. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 in the last ninety days. 4.60% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.